Push Admin

Philippines to start clinical trials on lagundi as supplement for COVID-19 patients

Article (news)

Arianne Merez, ABS-CBN News

<div class="embed-wrap"><figure data-feedback="fb:likes,fb:comments"><img src="http://sa.kapamilya.com/absnews/abscbnnews/media/2020/news/07/21/lagundi.jpg"/><figcaption>From the website of the DOST&#x27;s Philippine Council for Health Research and Development</figcaption></figure></div>MANILA - The Philippines will start by August clinical trials for lagundi or chaste tree as a supplemental treatment to COVID-19, the Department of Science and Technology said Tuesday.Lagundi is known to have anti-viral properties that could help in the treatment of COVID-19 particularly mild cases, Science Secretary Fortunato Dela Peña said.&quot;Ang aim ng study na sisimulan sa August 1 or earlier kung mailalabas na &#x27;yung FDA (Food and Drug Administration) clearance ay mapakita kung ito ay makakabuti para ma-address &#x27;yung mga symptoms, guminhawa yung pasyente doon sa kanilang pag-ubo at lagnat at sore throat,&quot; he said in a virtual press briefing.(The aim of the study which we will start by August 1 or earlier if the FDA could release the clearance is to see if it could help address symptoms such as coughing, fever, and sore throat.)Lagundi is commercially used as medicine for cough.<ul class="op-related-articles">	<li><a href="https://news.abs-cbn.com/video/news/06/11/20/tawa-tawa-lagundi-vs-covid-19-philippines-mulls-traditional-herbs-in-pandemic-fight">Tawa-tawa, lagundi vs COVID-19? Philippines mulls traditional herbs in pandemic fight</a></li></ul>Aside from lagundi, the DOST is also looking at tawa-tawa as a supplemental treatment for COVID-19 patients, Dela Peña said, but has yet to secure approval from the University of the Philippines Research Ethics Board.The country earlier stated clinical trials on the efficacy of virgin coconut oil for severe COVID-19 cases.<ul class="op-related-articles">	<li><a href="https://news.abs-cbn.com/news/06/03/20/virgin-coconut-oil-clinical-trials-for-severe-covid-19-cases-in-pgh-gets-greenlight">Virgin coconut oil clinical trials for severe COVID-19 cases in PGH gets greenlight</a></li></ul>As of July 20, the Philippines has 68,898 confirmed COVID-19 cases, of which 43,991 were active.The Philippines saw an increase in infections again since last month after the government eased lockdowns across the country to stimulate the economy dragged down by the pandemic.

The Philippines will start by August clinical trials for lagundi or chaste tree as a supplemental treatment to COVID-19, the Department of Science and Technology said Tuesday.

The Philippines will start by August clinical trials for lagundi or chaste tree as a supplemental treatment to COVID-19, the Department of Science and Technology said Tuesday.

Philippines to start clinical trials on lagundi as supplement for COVID-19 patients

News

Entertainment

Lifestyle

Sports

Metro.Style

More

Traffic

Manila

Horoscope

News

Philippines to start clinical trials on lagundi as supplement for COVID-19 patients

Arianne Merez,

ABS-CBN News

Published Jul 21, 2020 04:44 PM PHT

Read More:

lagundi

COVID-19 treatment

coronavirus treatment

DOST

lagundi COVID-19

lagundi trial coronavirus

lagundi DOST

ABS-CBN is the leading media and entertainment company in the Philippines, offering quality content across TV, radio, digital, and film. Committed to public service and promoting Filipino values, ABS-CBN continues to inspire and connect audiences worldwide.

Corporate

Investors

Governance

International Distribution

Corporate

Governance

Investors

International Distribution

NPC Seal of Registration

Privacy Policy

AI Policy

Terms of Service

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.